{
  "data": [
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219838,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220003,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220370,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221252,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Amantadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222274,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222696,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223028,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223029,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223031,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223032,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223033,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sulfadiazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223034,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223035,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223036,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223037,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223038,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223039,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223040,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223042,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223043,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223044,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223045,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Zafirlukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223046,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223047,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223048,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223049,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223051,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Testosterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223052,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223053,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Stavudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223056,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sevelamer",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223057,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sumatriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223058,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223059,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Tobramycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223060,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223061,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Tretinoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223062,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223066,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Tadalafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223067,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Temozolomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223068,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Terbinafine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223069,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223071,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Bimatoprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223072,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Zonisamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223073,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223075,
      "ingredient1": "salmeterol"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 1471,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 6840,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 14858,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 15884,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21619,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Atazanavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26291,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bepridil",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26299,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26302,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26324,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cobicistat",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26331,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Conivaptan",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26332,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26362,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26381,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26403,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26410,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nefazodone",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26450,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Papaverine",
      "severity": "Major",
      "effect": "Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.",
      "management_text": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26476,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26489,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Major",
      "effect": "Coadministration with quinidine may increase the concentrations of loperamide in plasma and central nervous system (CNS). Opioid and other adverse effects may be enhanced. The proposed mechanism is inhibition of P-glycoprotein (P-gp) efflux transporter by quinidine, resulting in increased gastrointestinal absorption as well as increased penetration of loperamide across the blood brain barrier. The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval such as quinidine or quinine may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "Caution is recommended if loperamide is used with quinidine, a drug that can prolong the QT interval as well as increase the plasma and CNS concentrations of loperamide. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26505,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26531,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Telaprevir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26533,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26535,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Troleandomycin",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26556,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26283,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26320,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26329,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26336,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26344,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26350,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26374,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26406,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nelfinavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26451,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Quinine",
      "severity": "Major",
      "effect": "Coadministration with quinidine may increase the concentrations of loperamide in plasma and central nervous system (CNS). Opioid and other adverse effects may be enhanced. The proposed mechanism is inhibition of P-glycoprotein (P-gp) efflux transporter by quinidine, resulting in increased gastrointestinal absorption as well as increased penetration of loperamide across the blood brain barrier. The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval such as quinidine or quinine may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "Caution is recommended if loperamide is used with quinidine, a drug that can prolong the QT interval as well as increase the plasma and CNS concentrations of loperamide. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26506,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26512,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26528,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Major",
      "effect": "Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central nervous system (CNS). Inhibition of P-gp in the intestine increases the systemic absorption of loperamide, while inhibition in the blood brain barrier facilitates loperamide entry into the CNS. Opioid and other adverse effects may be enhanced.",
      "management_text": "Caution is recommended if loperamide is used with potent P-gp inhibitors. Particular caution is advised when drugs that inhibit other pathways of loperamide elimination (CYP450 2C8; CYP450 3A4) are also used, since they may act synergistically with P-gp inhibitors to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. \"",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26567,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Major",
      "effect": "Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.",
      "management_text": "Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 26568,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Chlorpheniramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 3742,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 4788,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acrivastine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7675,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12198,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12651,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.",
      "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15356,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fostemsavir",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15425,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gemifloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15956,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16058,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Phenyltoloxamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16600,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22066,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Apraclonidine",
      "severity": "Moderate",
      "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.",
      "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26286,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Aripiprazole",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26287,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Arsenic trioxide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26288,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Asenapine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26289,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bedaquiline",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26296,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Belladonna",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26297,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26300,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26303,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Brexanolone",
      "severity": "Moderate",
      "effect": "Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions. Patients treated with brexanolone are at risk of excessive sedation or sudden loss of consciousness during administration.",
      "management_text": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation. Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring. During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation. After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate. If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia. Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26304,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Brexpiprazole",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26305,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Moderate",
      "effect": "Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter 1 (OCT1), and/or multidrug and toxin extrusion protein 1 (MATE1), and 2K (MATE2K). The proposed mechanism, based on in vitro data, is decreased drug clearance due to brigatinib-mediated inhibition of these transport proteins.",
      "management_text": "Caution is advised if brigatinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OCT 1, MATE 1, and/or MATE 2K transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever brigatinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26306,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26310,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cabozantinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26312,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Moderate",
      "effect": "Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as digoxin and rosuvastatin. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of intestinal P-gp and/or BCRP efflux transport proteins.",
      "management_text": "Coadministration of capmatinib with drugs that are substrates of P-gp and/or BCRP should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26313,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26315,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Chlorcyclizine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26316,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clofazimine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26327,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26328,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26333,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cyclizine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26334,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26335,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Daclatasvir",
      "severity": "Moderate",
      "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.",
      "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26338,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26340,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Degarelix",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26343,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26345,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Deutetrabenazine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26347,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26351,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26352,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26356,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26357,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26359,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Elagolix",
      "severity": "Moderate",
      "effect": "Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by elagolix.",
      "management_text": "Caution is advised when elagolix is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elagolix is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26365,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Eliglustat",
      "severity": "Moderate",
      "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.",
      "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26366,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Eluxadoline",
      "severity": "Moderate",
      "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.",
      "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26367,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26368,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26369,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.",
      "management_text": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26370,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Erdafitinib",
      "severity": "Moderate",
      "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp.",
      "management_text": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26372,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Eribulin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26373,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26375,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Esketamine",
      "severity": "Moderate",
      "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.",
      "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26376,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26377,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26378,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Flavoxate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26379,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26380,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26386,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26387,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Glycopyrronium",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26388,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26390,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Halofantrine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26392,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Halothane",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26394,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Histrelin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26395,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26396,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26398,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ibrutinib",
      "severity": "Moderate",
      "effect": "Coadministration with ibrutinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. In vitro studies indicate that ibrutinib is not a substrate for P-gp, and systemic ibrutinib is unlikely to be an inhibitor of P-gp at clinical doses.",
      "management_text": "Caution is advised if ibrutinib is prescribed in combination with orally administered P-gp substrates, particularly those with a narrow therapeutic range. Dosage reduction and/or dosage interval adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ibrutinib is added to or withdrawn from therapy. Some authorities recommend that narrow therapeutic range P-gp substrates, such as digoxin, should be administered at least 6 hours before or after ibrutinib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26400,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26402,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26404,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26407,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Moderate",
      "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.",
      "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26408,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Istradefylline",
      "severity": "Moderate",
      "effect": "Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.",
      "management_text": "Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26409,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Moderate",
      "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.",
      "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26411,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Macimorelin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26430,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Maprotiline",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26431,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mepenzolate",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26434,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mesoridazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26436,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methdilazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26438,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methotrimeprazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26439,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methscopolamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26440,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Metronidazole",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26441,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Midostaurin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26442,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Molindone",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26445,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nalbuphine",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26449,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Neratinib",
      "severity": "Moderate",
      "effect": "Coadministration with neratinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by neratinib.",
      "management_text": "Caution is advised when neratinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever neratinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26452,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nilotinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26453,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Norfloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26455,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ofloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26457,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oliceridine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26459,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Olodaterol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26460,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ondansetron",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26462,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Opium",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26463,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Orphenadrine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26464,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Osilodrostat",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26465,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Osimertinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26466,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxybutynin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26468,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxymorphone",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26470,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ozanimod",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26472,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Paliperidone",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26473,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Panobinostat",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26475,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pasireotide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26477,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pazopanib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26478,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Perphenazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26482,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Phenindamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26483,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Physostigmine",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26484,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pimavanserin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26485,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pimozide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26486,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pitolisant",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26487,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ponatinib",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, coadministration with ponatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ponatinib.",
      "management_text": "Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ponatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26488,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pramlintide",
      "severity": "Moderate",
      "effect": "The use of pramlintide in combination with drugs that alter gastrointestinal motility (e.g., loperamide; anticholinergic agents) or drugs that slow the intestinal absorption of nutrients (e.g., alpha-glucosidase inhibitors) has not been studied.",
      "management_text": "Due to its effect on gastric emptying, pramlintide therapy should not be considered for patients taking drugs that alter gastrointestinal motility or drugs that slow the intestinal absorption of nutrients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26490,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Primaquine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26491,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Probucol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26492,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Procainamide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26493,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26497,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Propafenone",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26498,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mepyramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26503,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26504,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ribociclib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26509,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rilpivirine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26510,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rivastigmine",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26513,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rolapitant",
      "severity": "Moderate",
      "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.",
      "management_text": "Caution is advised when rolapitant is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26514,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Romidepsin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26515,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rucaparib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26516,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Moderate",
      "effect": "Coadministration with loperamide may decrease the plasma concentrations of saquinavir. The mechanism of interaction is unknown, but may be mediated by the effects of loperamide on gastrointestinal motility and fluids. The renal clearance and elimination half-life of saquinavir were not affected. The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval such as saquinavir may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, prolonged use of loperamide should preferably be avoided in patients treated with saquinavir. However, the effect of loperamide on the pharmacokinetics of ritonavir-boosted saquinavir is unknown. Caution is recommended if coadministration is required. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26517,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sarecycline",
      "severity": "Moderate",
      "effect": "Coadministration with sarecycline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by sarecycline.",
      "management_text": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sarecycline is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26518,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26520,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26521,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sevoflurane",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26522,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26523,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Solifenacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26524,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sparfloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26527,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sunitinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26529,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Telavancin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26534,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Terbutaline",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26536,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tetrabenazine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26538,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Thiothixene",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26541,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Moderate",
      "effect": "Coadministration with tipranavir in combination with low-dose ritonavir may decrease the plasma concentrations of loperamide. The mechanism probably involves reduced absorption and increased first-pass clearance of loperamide due to induction of the intestinal P-glycoprotein drug efflux pump by tipranavir.",
      "management_text": "Clinicians and patients should be aware that pharmacologic effects of loperamide may be reduced during coadministration with tipranavir/ritonavir.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26542,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26544,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Triclabendazole",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26547,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26551,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Triptorelin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26555,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tucatinib",
      "severity": "Moderate",
      "effect": "Coadministration with tucatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The mechanism likely involves tucatinib-mediated inhibition of P-gp. Increased exposure to the P-gp substrate may increase the risk of toxicity.",
      "management_text": "Caution is advised if tucatinib is used concomitantly with P-gp substrates, particularly those with a narrow therapeutic index. A dose reduction of the P-gp substrates as well as clinical and laboratory monitoring may be appropriate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26558,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ulipristal",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ulipristal.",
      "management_text": "Caution is advised when ulipristal is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ulipristal is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26559,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Valbenazine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26560,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vandetanib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26561,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vardenafil",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26562,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26564,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Venetoclax",
      "severity": "Moderate",
      "effect": "Coadministration with venetoclax may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of P-glycoprotein-mediated drug efflux in the intestine, liver, and/or kidney by venetoclax.",
      "management_text": "Caution is advised when venetoclax is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate. Alternatives should be considered whenever possible. The manufacturer recommends that drugs sensitive to P-gp inhibition in the gastrointestinal tract be administered at least 6 hours before venetoclax. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate following the initiation or discontinuation of venetoclax.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26565,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Lumefantrine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31936,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Benzhydrocodone",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41041,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cilostazol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65330,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tolvaptan",
      "severity": "Moderate",
      "effect": "Coadministration with tolvaptan may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of P-glycoprotein-mediated drug efflux in the intestine, liver, and/or kidney by tolvaptan.",
      "management_text": "Caution is advised when tolvaptan is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate. Alternatives should be considered whenever possible. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate following the initiation or discontinuation of tolvaptan. The prescribing information for the coadministered drug should be consulted for specific dosing recommendations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111021,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval.  Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval.  Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes.  Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.  In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 250995,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Relugolix",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval.  Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval.  Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes.  Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.  In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 250996,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Homatropine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).  Ambulatory patients should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300454,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Codeine",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5225,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5945,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Foscarnet",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15017,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15712,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16266,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Moderate",
      "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.",
      "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17470,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22516,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24825,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hyoscyamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25359,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Propofol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25749,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Abarelix",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26281,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26282,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Astemizole",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26290,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Atomoxetine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26292,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Atropine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26293,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Azatadine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26294,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Azithromycin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26295,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Benzatropine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26298,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Biperiden",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26301,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Brimonidine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.",
      "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness. Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26307,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Brompheniramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26309,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26311,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Carbinoxamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26314,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26317,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26318,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26321,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cisapride",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26322,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26323,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clemastine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26325,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clidinium",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26326,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26330,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cyproheptadine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26337,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26339,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Daunorubicin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26341,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Desmopressin",
      "severity": "Moderate",
      "effect": "Coadministration with opiates may increase the plasma concentrations and pharmacologic effects of oral desmopressin. The risk of water intoxication and/or hyponatremia may be increased.",
      "management_text": "Caution is recommended if desmopressin is used in combination with opiates. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek immediate medical attention if they develop early signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, drowsiness, lethargy, weakness, listlessness, headache, confusion, difficulty concentrating, memory impairment, anuria, and weight gain. Early treatment may help prevent progression to seizure, coma, respiratory arrest, and death.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26346,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dexbrompheniramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26348,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26349,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26353,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26354,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26355,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Doxylamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26361,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26363,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26364,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Epirubicin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26371,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26382,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26383,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26384,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26385,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26389,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Grepafloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26391,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26393,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26397,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26399,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ibutilide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26401,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26405,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Loxapine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26429,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Meclizine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26432,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mefloquine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26433,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Meperidine",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26435,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methadone",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26437,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mifepristone",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26443,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mirtazapine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26444,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Morphine",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26446,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Moxifloxacin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26448,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nilutamide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26454,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nortriptyline",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26456,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Olanzapine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26458,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Olopatadine (nasal)",
      "severity": "Moderate",
      "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.",
      "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26461,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxaliplatin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26467,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxycodone",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26469,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxytocin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26471,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Palonosetron",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26474,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pentamidine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26479,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pentazocine",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26480,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Perflutren",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26481,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26494,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Procyclidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26495,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Promazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26496,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Propantheline",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26499,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Propiomazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26500,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26501,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Protriptyline",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26502,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26508,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26511,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Scopolamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26519,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sorafenib",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26525,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26526,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tacrine",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26530,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tamoxifen",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26532,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Terfenadine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26537,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Thiethylperazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26539,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26540,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Moderate",
      "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.",
      "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26543,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Toremifene",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26545,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26546,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26548,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Triflupromazine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26549,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Trihexyphenidyl",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26550,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Trimipramine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26552,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tripelennamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26553,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Triprolidine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26554,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Trospium",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26557,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vasopressin",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26563,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26566,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.",
      "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26569,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Berotralstat",
      "severity": "Moderate",
      "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of the efflux transporter P-glycoprotein (P-gp).  The mechanism is decreased clearance due to inhibition of P-gp activity by berotralstat.",
      "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of P-gp, particularly those with a narrow therapeutic index.  This interaction has only been reported at twice the recommended daily dose of berotralstat.  Clinical and laboratory monitoring should be considered following the initiation or discontinuation of berotralstat, and the individual dosage of the concomitant agents adjusted as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 250983,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fidaxomicin",
      "severity": "Moderate",
      "effect": "Coadministration with fidaxomicin may increase the plasma concentrations of some orally administered drugs that are substrates of the P-glycoprotein (P-gp) transporter.  In vitro, fidaxomicin and its main metabolite are substrates and inhibitors of P-gp, an efflux transporter expressed in the gastrointestinal tract.",
      "management_text": "Caution is advised when fidaxomicin is used in combination with P-gp substrates that may be sensitive to intestinal P-gp inhibition.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 250987,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cholestyramine",
      "severity": "Minor",
      "effect": "Cholestyramine may bind to loperamide in the gastrointestinal tract. The efficacy of loperamide in treating diarrhea may be reduced. If concomitant use is necessary, loperamide should be administered at least two hours before cholestyramine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 26319,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220128,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dacarbazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220129,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Temozolomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220130,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Terbinafine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220131,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220132,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220133,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220134,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Risedronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220135,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220136,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bimatoprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220137,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zonisamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220138,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Paricalcitol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220139,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220140,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Misoprostol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220141,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220142,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rizatriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220143,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220144,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methylprednisolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220145,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zaleplon",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220146,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220147,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Desloratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220148,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methyldopa",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220149,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Selenium Sulfide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220150,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220151,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220152,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cromoglicic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220153,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cinacalcet",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220154,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Balsalazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220155,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220156,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Phylloquinone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220157,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mycophenolic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220158,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mercaptopurine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220159,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220160,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Memantine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220161,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tegaserod",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220162,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220163,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rosuvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220164,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220165,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Miconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220166,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nifedipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220167,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Atovaquone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220168,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dutasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220169,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220170,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220171,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Terazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220172,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Calcium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220173,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Naloxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220174,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zopiclone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220175,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nadolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220177,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mitoxantrone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220178,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Paclitaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220179,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Metoclopramide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220180,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sodium bicarbonate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220181,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tiotropium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220182,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefpodoxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220183,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ursodeoxycholic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220184,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nitrazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220185,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Valganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220186,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220187,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clobetasol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220188,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220189,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221239,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221497,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221735,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222914,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223273,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223581,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Alosetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224180,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224634,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Azathioprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224880,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225059,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225462,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225916,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225994,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226319,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226606,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226811,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227139,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227750,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228019,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228283,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228455,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228709,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Atorvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228916,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Etidronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229075,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229794,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230147,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Econazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230525,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230967,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231507,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232266,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acebutolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232405,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232652,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233207,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233365,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233524,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233894,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234491,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234660,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234928,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235200,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefepime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235591,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acetylcysteine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236301,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vitamin D",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236557,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Galactose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236694,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194748,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194989,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195236,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vitamin A",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195365,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Baclofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195863,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nicotine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196078,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197793,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dapsone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198442,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198557,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198753,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198956,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Carmustine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199074,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200523,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acetaminophen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200914,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201465,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Atenolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201982,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203533,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203785,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203992,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204330,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ceftazidime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205420,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205590,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205655,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207456,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dicloxacillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207711,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207841,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefotaxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208005,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Dextromethorphan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208525,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208813,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209440,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210116,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210376,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210820,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211218,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211524,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211726,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212099,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Niacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212581,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212932,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Epinephrine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214267,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214765,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215097,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216316,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mannitol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216457,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217500,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217741,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217980,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218329,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218638,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219076,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219306,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219820,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219995,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Octreotide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220033,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pravastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220034,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220035,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220036,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Lorazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220037,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220038,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Hydroxocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220039,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220040,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Adapalene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220041,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pantoprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220042,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220043,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gadodiamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220044,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Lovastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220045,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pregabalin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220046,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220047,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nevirapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220048,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mesalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220049,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Metoprolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220050,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ropinirole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220051,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220052,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pamidronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220053,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Mitomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220054,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zolmitriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220055,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220056,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Piperacillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220057,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Metformin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220058,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220059,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220060,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220061,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Timolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220062,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Treprostinil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220063,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Progesterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220064,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220065,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nisoldipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220066,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220067,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pramipexole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220068,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methylphenidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220069,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methocarbamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220070,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220071,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220072,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Trimethoprim",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220073,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Montelukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220075,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220076,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Raloxifene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220078,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Zidovudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220079,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220080,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220081,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Metolazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220082,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220083,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220084,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220085,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220086,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220087,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220088,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Methotrexate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220089,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220090,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220091,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220092,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220094,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220095,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220096,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220097,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Testosterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220098,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220099,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220100,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pemetrexed",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220101,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nystatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220102,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Stavudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220103,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sevelamer",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220104,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sumatriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220105,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Aprepitant",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220106,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Losartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220107,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220108,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tobramycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220109,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nitrofurantoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220110,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220111,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220112,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxacillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220113,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Paroxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220114,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Imiquimod",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220115,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nitroglycerin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220116,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Nateglinide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220117,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Modafinil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220118,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Potassium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220119,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Oxcarbazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220120,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Perindopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220121,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Primidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220122,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220123,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Pentoxifylline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220124,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Ribavirin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220125,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Meloxicam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220126,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Tadalafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220127,
      "ingredient1": "Loperamide"
    },
    {
      "ingredient2": "Acetazolamide",
      "severity": "Major",
      "effect": "Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase inhibitors can decrease serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Theoretically, metformin-induced lactic acidosis may be more likely in this setting, albeit still rare.",
      "management_text": "Caution is advised if metformin is used concomitantly with carbonic anhydrase inhibitors. Close monitoring for the development of lactic acidosis is recommended, particularly in the elderly and patients with other risk factors such as unstable or acute congestive heart failure or other conditions that can lead to hypoperfusion and hypoxemia. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 6331,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Major",
      "effect": "Alcohol can potentiate the effect of metformin on lactate metabolism and increase the risk of lactic acidosis. In addition, alcohol may cause hypoglycemia or hyperglycaemia in patients with diabetes. Although hypoglycemia rarely occurs during treatment with metformin alone, the risk may increase with acute consumption of alcohol. Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise. The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.",
      "management_text": "Excessive alcohol intake should be avoided during treatment with metformin. Diabetes patients in general should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis. Alcohol should not be consumed on an empty stomach or following exercise, as it may increase the risk of hypoglycemia. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 12670,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diclofenamide",
      "severity": "Major",
      "effect": "Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase inhibitors can decrease serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Theoretically, metformin-induced lactic acidosis may be more likely in this setting, albeit still rare.",
      "management_text": "Caution is advised if metformin is used concomitantly with carbonic anhydrase inhibitors. Close monitoring for the development of lactic acidosis is recommended, particularly in the elderly and patients with other risk factors such as unstable or acute congestive heart failure or other conditions that can lead to hypoperfusion and hypoxemia. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18024,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Major",
      "effect": "Gatifloxacin may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of various quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.",
      "management_text": "The use of gatifloxacin is contraindicated in patients with diabetes mellitus. Other quinolones may be safer alternatives in such patients, although all quinolones should be used with caution. Blood glucose should be closely monitored whenever quinolones are prescribed to patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18058,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iodipamide",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18088,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iodixanol",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18089,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18090,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18091,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18092,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iothalamic acid",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18093,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ioversol",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18094,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ioxilan",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18095,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Zonisamide",
      "severity": "Major",
      "effect": "Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase inhibitors can decrease serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Theoretically, metformin-induced lactic acidosis may be more likely in this setting, albeit still rare.",
      "management_text": "Caution is advised if metformin is used concomitantly with carbonic anhydrase inhibitors. Close monitoring for the development of lactic acidosis is recommended, particularly in the elderly and patients with other risk factors such as unstable or acute congestive heart failure or other conditions that can lead to hypoperfusion and hypoxemia. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18224,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diatrizoate",
      "severity": "Major",
      "effect": "Administration of intravascular iodinated radiocontrast media in patients treated with biguanides such as metformin may precipitate lactic acidosis, a rare but potentially serious and fatal complication of biguanide therapy. Iodinated contrast material can cause acute alterations in renal function, including acute renal failure, which is a known risk factor for biguanide-induced lactic acidosis.",
      "management_text": "Biguanide therapy should be temporarily discontinued at the time of, or prior to, radiographic studies involving intravascular administration of iodinated contrast media, and not resumed until at least 48 hours after the procedure and renal function has been re-evaluated and determined to be normal.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18022,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Major",
      "effect": "Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase inhibitors can decrease serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Use of topiramate, a carbonic anhydrase inhibitor, in epilepsy and migraine prophylaxis has frequently caused dose-dependent metabolic acidosis in both adult and pediatric patients in controlled trials. Theoretically, metformin-induced lactic acidosis may be more likely in this setting, albeit still rare.Pharmacokinetically, topiramate may increase the plasma concentrations of metformin. Topiramate pharmacokinetics were not affected.",
      "management_text": "Caution is advised if metformin is used concomitantly with carbonic anhydrase inhibitors including topiramate. Close monitoring for the development of lactic acidosis is recommended, particularly in the elderly and patients with other risk factors such as unstable or acute congestive heart failure or other conditions that can lead to hypoperfusion and hypoxemia. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 18205,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dolutegravir",
      "severity": "Moderate",
      "effect": "Coadministration with dolutegravir may decrease the renal elimination of metformin resulting in increased metformin plasma concentrations and an increased risk of lactic acidosis. The proposed mechanism is dolutegravir-mediated inhibition of the renal organic cation transporter 2 (OCT2) of which metformin is a substrate.",
      "management_text": "Caution is advised if dolutegravir must be used concurrently with metformin. The dose of metformin may require adjustment whenever dolutegravir is added to or withdrawn from therapy, especially in patients with risk factors for increased metformin levels. One manufacturer recommends the total daily dose of metformin be limited to 1000 mg if these drugs must be used together. Clinical and laboratory monitoring, including renal function and blood glucose monitoring should be performed when these drugs are used concomitantly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 140,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Abemaciclib",
      "severity": "Moderate",
      "effect": "Coadministration with abemaciclib may increase the plasma concentrations of metformin. The proposed mechanism is abemaciclib inhibition of OCT 2, MATE 1 and MATE 2-K, the renal transporters involved in the active tubular secretion of metformin.",
      "management_text": "Caution is advised when metformin is used with abemaciclib. Dose adjustments of metformin as well as clinical and laboratory monitoring of glycemic control may be appropriate whenever abemaciclib is added to or withdrawn from therapy. Patients should be advised to be alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitations, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1195,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Phenylephrine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 3761,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ranitidine",
      "severity": "Moderate",
      "effect": "Ranitidine is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for ranitidine, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If ranitidine and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6848,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Formoterol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7383,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pseudoephedrine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7687,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nifedipine",
      "severity": "Moderate",
      "effect": "Nifedipine may increase plasma concentrations of metformin by increasing the extent of absorption. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If nifedipine and metformin must be used together, cautious titration of metformin dosage is recommended. Increased metformin levels may increase the risk of lactic acidosis. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 8872,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Epinephrine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10057,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10330,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10878,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11312,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12211,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17177,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Acetohexamide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17965,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Aloe Vera Leaf",
      "severity": "Moderate",
      "effect": "Concomitant use of oral products containing aloe vera gel may potentiate the hypoglycemic effect of insulin and other antidiabetic agents.",
      "management_text": "Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia. Patients should be monitored for changes in diabetic medication requirements.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17966,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Alpelisib",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17967,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Moderate",
      "effect": "Amiloride is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "Particularly slow and cautious titration of metformin dosage is recommended if these drugs must be used together. The maximal dose of metformin should also be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17970,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17971,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Moderate",
      "effect": "Coadministration with metformin may decrease the anticoagulant effects of vitamin K antagonists (VKAs). The mechanism has not been delineated, but it may involve metformin-mediated increase in the elimination rate of VKAs. In addition, concomitant use of VKAs with metformin may increase the risk of severe hypoglycemia. The clinical significance of this interaction is unknown.",
      "management_text": "Until more information is available, patients receiving VKAs with metformin should be closely monitored during concomitant therapy. The INR or prothrombin time should be checked frequently and the VKA dosage adjusted accordingly, particularly following initiation, change of dosage, or discontinuation of metformin therapy. In addition, patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17972,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Aripiprazole",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17973,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Asenapine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17974,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Asparaginase Erwinia chrysanthemi",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17975,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Atazanavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17976,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bendroflumethiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17977,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Benzphetamine",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17978,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17979,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Brentuximab vedotin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17981,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Brexpiprazole",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17982,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17983,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17984,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17985,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Calaspargase pegol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17986,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Moderate",
      "effect": "Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of multidrug and toxin extrusion 1 and 2K (MATE1 and MATE2K) proteins, such as methylnaltrexone and tipiracil. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of MATE1 and/or MATE2K.",
      "management_text": "Coadministration of capmatinib with drugs that are substrates of MATE1 and/or MATE2K should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and the dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17987,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17988,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Cariprazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17989,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17990,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Moderate",
      "effect": "The concomitant administration of cephalexin may increase plasma concentrations and adverse effects of metformin. The mechanism is competitive inhibition of active renal tubular secretion.",
      "management_text": "Patients receiving this combination should be monitored for altered efficacy and safety of metformin. Metformin dose adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17991,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17992,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Chlorothiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17993,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17994,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17995,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Chromic chloride",
      "severity": "Moderate",
      "effect": "Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.",
      "management_text": "Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17997,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Chromium picolinate",
      "severity": "Moderate",
      "effect": "Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.",
      "management_text": "Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17998,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Moderate",
      "effect": "Cimetidine may significantly reduce the renal tubular secretion of metformin. The mechanism may involve cimetidine inhibition of the organic cation transporter 2 (OCT2), thereby increasing metformin plasma concentration. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "Particularly slow and cautious titration of metformin dosage is recommended if these drugs must be used together. The maximal dose of metformin should also be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as nausea, vomiting, malaise, myalgia, weakness, respiratory distress, slow or irregular heartbeat, dizziness, lightheadedness, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17999,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18000,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Moderate",
      "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.",
      "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18001,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18004,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Colesevelam",
      "severity": "Moderate",
      "effect": "Coadministration with colesevelam may increase the plasma concentrations of metformin. The mechanism of interaction has not been described.",
      "management_text": "Caution is advised if metformin is used concomitantly with colesevelam. Clinical response and tolerance to metformin should be monitored more closely following the initiation or discontinuation of colesevelam. Patients should be advised to contact their physician if they experience increased side effects of metformin such as nausea, vomiting, diarrhea, flatulence, indigestion, and asthenia. Immediate medical attention should be sought if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, somnolence, abdominal distress, respiratory distress, hyperventilation, slow or irregular heartbeat, and hypothermia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18005,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Copanlisib",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18007,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tetracosactide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18008,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Moderate",
      "effect": "Coadministration with crizotinib may theoretically increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2B6 (e.g., bupropion), P-glycoprotein (P-gp) (e.g., dabigatran), and/or the organic cation transporters 1 and 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism, based on in vitro data, is decreased clearance due to crizotinib-mediated inhibition of CYP450 2B6, P-gp, and/or OCT1 or OCT2.",
      "management_text": "Although the clinical significance is unknown, caution is advised if crizotinib is used concomitantly with drugs that are substrates of CYP450 2B6, P-gp, and/or OCT1 or OCT2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever crizotinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18009,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas.",
      "management_text": "Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18010,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Daclatasvir",
      "severity": "Moderate",
      "effect": "Coadministration with daclatasvir may increase the systemic exposure and risk of adverse effects of drugs that are substrates of the hepatic uptake transporter, organic cation transporter 1 (OCT1). The proposed mechanism is decreased clearance due to daclatasvir-mediated inhibition of OCT1. The clinical significance is unknown.",
      "management_text": "Caution is advised if daclatasvir is used concomitantly with drugs that are substrates of OCT1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever daclatasvir is added to or withdrawn from therapy with these drugs. Patients should also be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18011,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dalfampridine",
      "severity": "Moderate",
      "effect": "The concomitant use of dalfampridine with drugs that are inhibitors of organic cation transporter 2 (OCT2) may theoretically reduce its renal clearance. Dalfampridine is primarily eliminated through renal excretion, approximately 60% of which is via active secretion by OCT2. Elevated levels of dalfampridine may increase the risk of CNS excitation and seizures.",
      "management_text": "Caution is advised when dalfampridine is used with OCT2 inhibitors. The benefit of concomitant use should be weighed against the potential risk of seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18012,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18013,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18014,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Delafloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18015,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18018,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dexfenfluramine",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18021,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diazoxide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18023,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18025,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dienestrol (topical)",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18027,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diethylpropion",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18028,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18031,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Moderate",
      "effect": "Digoxin is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. In addition, patients who are being pharmacologically treated for congestive heart failure appear to be at greater risk of developing lactic acidosis.",
      "management_text": "If digoxin and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to promptly notify their physician if they experience malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18032,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dobutamine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18033,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18035,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Moderate",
      "effect": "Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.",
      "management_text": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18036,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Enfortumab vedotin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18037,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Entecavir",
      "severity": "Moderate",
      "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18038,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ephedrine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18039,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Erdafitinib",
      "severity": "Moderate",
      "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2), resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of OCT2. However, no pharmacokinetic data are available from drug interaction studies.",
      "management_text": "Concomitant use of erdafitinib and OCT2 substrates should generally be avoided or the dose of the OCT2 substrates should be reduced based on tolerability.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18040,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18041,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Estrone sulfate",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18043,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18045,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18046,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Everolimus",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18048,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18049,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18051,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18052,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18054,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18055,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "One study has suggested that furosemide may increase plasma concentrations of metformin by 22% (without changes in metformin clearance) and that metformin may decrease the peak concentration and elimination half-life of furosemide by 31% and 32%, respectively. The clinical implications of these findings are uncertain. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If furosemide and metformin must be used together, it is recommended that the clinician observe closely for evidence that the effects of either drug have been altered. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18056,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Gemifloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18059,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ginseng",
      "severity": "Moderate",
      "effect": "Coadministration of ginseng with antidiabetic drugs may potentiate the risk of hypoglycemia. Clinical data are conflicting. Some small studies have reported that ginseng reduced the blood levels of glucose and/or glycosylated hemoglobin (HbA1C) in diabetic patients, whereas others have not. Furthermore, the lack of standardized preparations of ginseng may limit the generalization of study results.",
      "management_text": "Until more information is available, blood glucose should be monitored if antidiabetic agents are used concomitantly with ginseng. Patients should be advised on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia), how to treat it, and to contact their doctor if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18060,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18062,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18063,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Grepafloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18064,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Moderate",
      "effect": "Coadministration with guanfacine may theoretically increase the plasma concentrations and risk of adverse effects of drugs that are substrates of the hepatic uptake transporter, organic cation transporter 1 (OCT1). The proposed mechanism is decreased clearance due to guanfacine-mediated inhibition of OCT1. Based on in vitro data, guanfacine may be an inhibitor of OCT1 at maximal portal vein concentrations. Concomitant use of guanfacine with OCT1 substrates with a similar time to maximum concentration (Tmax) (e.g., metformin), may increase the maximum plasma concentration (Cmax) of these medicines. The clinical significance of this interaction is unknown.",
      "management_text": "Caution is advised if guanfacine is used concomitantly with drugs that are substrates of OCT1, such as metformin. Dosage adjustment and monitoring may be required whenever guanfacine is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18065,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Moderate",
      "effect": "Morphine is a cationic drug and theoretically may decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for morphine, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If morphine and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18066,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Histrelin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18067,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Hydroflumethiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18068,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18069,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Indacaterol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18070,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18071,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18075,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18077,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18078,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18080,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Moderate",
      "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentration and effects of metformin. The proposed mechanism is inhibition of organic cation transporter 2 (OCT2)-mediated elimination by isavuconazole.",
      "management_text": "Caution is advised if isavuconazonium sulfate (prodrug of isavuconazole) is used concomitantly with metformin. Dose adjustments of metformin as well as clinical and laboratory monitoring of glycemic control may be appropriate whenever isavuconazole sulfate is added to or withdrawn from therapy. Patients should be advised to be alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitations, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18096,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18097,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methotrimeprazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18123,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methoxamine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18124,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methylprednisolone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18125,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Midostaurin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18127,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Moexipril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18128,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nabumetone",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18131,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18132,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nateglinide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18133,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Norethisterone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18135,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Norfloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18136,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Norgestrel",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18137,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ofloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18139,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Olanzapine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18140,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Olaparib",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.",
      "management_text": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18141,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Omacetaxine mepesuccinate",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18142,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Orlistat",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18143,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ospemifene",
      "severity": "Moderate",
      "effect": "Ospemifene and its major metabolite, 4-hydroxyospemifene, may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic cation transporter (OCT)1, uridine diphosphate glucuronosyltransferase (UGT) 1A3, and/or UGT1A9. The proposed mechanism, based on in vitro data, is decreased clearance due to ospemifene-mediated inhibition of OCT1, UGT1A3, and/or UGT1A9.",
      "management_text": "Until more information is available, caution is advised when ospemifene is used concomitantly with drugs that are substrates of OCT1, UGT1A3, and/or UGT1A9, particularly those with a narrow therapeutic range. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18144,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18145,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Paliperidone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18146,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pasireotide",
      "severity": "Moderate",
      "effect": "Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).",
      "management_text": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer's product labeling, and the antidiabetic treatment adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18147,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Patiromer",
      "severity": "Moderate",
      "effect": "INTERVAL: Patiromer can bind to some orally administered drugs, which may decrease their gastrointestinal absorption and reduce their effectiveness.",
      "management_text": "Patiromer should be administered at least 3 hours before or 3 hours after other oral medications, particularly ciprofloxacin, levothyroxine, and metformin. Alternatives to patiromer or the other medications should be considered if adequate dosing separation is not possible. Otherwise, clinical response and/or blood levels should be monitored where possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18148,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pemetrexed",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18151,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pentamidine",
      "severity": "Moderate",
      "effect": "Pentamidine may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of pentamidine has been associated with disturbances in blood glucose homeostasis due to direct toxic effects on beta cells of the pancreas. Hypoglycemia, which may be severe and/or prolonged, as well as hyperglycemia and insulin-dependent diabetes mellitus, the latter of which may be irreversible, have been reported.",
      "management_text": "Blood glucose should be monitored closely during and after pentamidine therapy in patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during pentamidine therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18152,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Perindopril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18153,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Perphenazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18154,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pexidartinib",
      "severity": "Moderate",
      "effect": "Coadministration with pexidartinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of multidrug and toxin extrusion protein 1 (MATE1) and 2K (MATE2K) and organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1. The proposed mechanism, based on in vitro data, is decreased clearance due to pexidartinib-mediated inhibition of these transport proteins.",
      "management_text": "Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of MATE1, MATE2K, OATP1B1, OATP1B3, and OATP2B1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18155,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Phendimetrazine",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18156,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Phenylbutazone",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18158,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18160,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pitolisant",
      "severity": "Moderate",
      "effect": "Coadministration with pitolisant may increase plasma concentrations of substrates of the hepatic and intestinal uptake transporter, organic cation transporter 1 (OCT1). Pitolisant has demonstrated inhibitory potential towards OCT1 in vitro. The clinical significance of this effect has not been established.",
      "management_text": "Caution is recommended when pitolisant is administered with OCT1 substrates.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18161,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Porfimer sodium",
      "severity": "Moderate",
      "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.",
      "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18162,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18163,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18164,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Procainamide",
      "severity": "Moderate",
      "effect": "Procainamide is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for procainamide, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If procainamide and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18165,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18166,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Progesterone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18167,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Promazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18169,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18170,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18171,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Quinestrol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18172,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Moderate",
      "effect": "Quinidine is a cationic drug that theoretically could decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for quinidine, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If quinidine and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18173,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18176,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ribociclib",
      "severity": "Moderate",
      "effect": "Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of breast cancer resistance protein (BCRP), organic cation transporter-2 (OCT-2), multidrug and toxin extrusion 1 (MATE1), and/or bile salt efflux pump (BSEP) transporters. The proposed mechanism, based on in vitro data, is decreased clearance due to ribociclib-mediated inhibition of these transport proteins at clinically relevant concentrations.",
      "management_text": "Caution is advised if ribociclib is used concomitantly with drugs that are substrates of BCRP, OCT-2, MATE1, and/or BSEP transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever ribociclib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18177,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Rifampicin",
      "severity": "Moderate",
      "effect": "Coadministration with rifampin may increase the gastrointestinal absorption and therapeutic efficacy of metformin. The mechanism may involve rifampin-mediated induction of the organic cation transporter 1 (OCT1) in the gastrointestinal tract.",
      "management_text": "Until more information is available, caution is advised if rifampin and metformin are used concomitantly. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosage of metformin may be adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18178,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Risdiplam",
      "severity": "Moderate",
      "effect": "Coadministration with risdiplam may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of multidrug and toxin extrusion 1 and 2K (MATE1 and MATE2K) proteins. Based on in vitro data, risdiplam and its metabolite are MATE1 and MATE2K transport inhibitors. The proposed mechanism is decreased clearance due to risdiplam-mediated inhibition of MATE1 and/or MATE2K.",
      "management_text": "Coadministration of risdiplam with drugs that are substrates of MATE1 and/or MATE2K should generally be avoided. However, if concomitant use is unavoidable, monitor for drug-related toxicities and consider dosage reduction of the MATE1 or MATE2K substrate (based in the labeling of that drug) as needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18179,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18180,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ritonavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18181,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18182,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Rucaparib",
      "severity": "Moderate",
      "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of Multidrug and Toxin Extrusion (MATE) 1, MATE 2-K, organic cation transporter (OCT) 1, and/or OCT 2. The proposed mechanism, based on in vitro data, is decreased clearance due to rucaparib-mediated inhibition of these transport proteins. Rucaparib appears to be a potent inhibitor of MATE 1 and MATE2-K, a moderate inhibitor of OCT1, and a weak inhibitor of OCT2.",
      "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of MATE 1, MATE 2-K, OCT 1 and/or OCT 2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18183,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18184,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sibutramine",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18186,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18187,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Somapacitan",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18188,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Somatrem",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18189,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sparfloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18190,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18191,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18192,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18193,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tafenoquine",
      "severity": "Moderate",
      "effect": "Coadministration with tafenoquine may increase the plasma concentrations of drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters. Clinical drug interaction studies with tafenoquine and OCT2 and MATE substrates have not been conducted in humans. However, in vitro observations suggest the potential for increased concentrations of these substrates, which may result in increased toxicities. Specifically, tafenoquine inhibited metformin transport via human OCT2, MATE-1, and MATE2-K transporters in vitro.",
      "management_text": "Concomitant use of tafenoquine with OCT2 and MATE substrates should generally be avoided. If coadministration is required, patients should be monitored for drug-related toxicities and dosage reductions considered as needed in accordance with the product labeling of the coadministered drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18194,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tagraxofusp",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18195,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Temsirolimus",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18196,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Teprotumumab",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18197,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tesamorelin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18198,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18199,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Thyroid, porcine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18200,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18202,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tolbutamide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18203,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tolmetin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18204,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trandolapril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18206,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18207,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Triamterene",
      "severity": "Moderate",
      "effect": "Triamterene is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for triamterene, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If triamterene and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18209,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18210,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Triflupromazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18211,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trimethoprim",
      "severity": "Moderate",
      "effect": "Trimethoprim may decrease the excretion of metformin by competing for renal tubular transport. The mechanism may involve trimethoprim inhibition of the organic cation transporter 2 (OCT2), thereby increasing metformin plasma concentration. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If trimethoprim and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18212,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Triptorelin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18213,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trovafloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18215,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Turmeric",
      "severity": "Moderate",
      "effect": "Coadministration of turmeric with antidiabetic drugs might potentiate the risk of hypoglycemia.",
      "management_text": "Blood glucose should be monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18216,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18217,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Moderate",
      "effect": "Vancomycin is a cationic drug and theoretically could decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for vancomycin, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If vancomycin and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18218,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vandetanib",
      "severity": "Moderate",
      "effect": "Coadministration with vandetanib may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2). The mechanism is inhibition of OCT2-mediated renal tubular secretion by vandetanib.",
      "management_text": "Caution is advised when vandetanib is used with drugs that are substrates of OCT2, particularly those with a narrow therapeutic range such as metformin. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vandetanib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18219,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Moderate",
      "effect": "Verapamil may decrease the glucose-lowering effects of metformin. The mechanism may involve verapamil inhibition of the organic cation transporter 1 (OCT1), thereby inhibiting hepatic uptake of metformin.",
      "management_text": "Caution is advised if verapamil and metformin are used concomitantly. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages may be adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18220,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vorinostat",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18221,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Moderate",
      "effect": "Coadministration with metformin may decrease the anticoagulant effects of vitamin K antagonists (VKAs). The mechanism has not been delineated, but it may involve metformin-mediated increase in the elimination rate of VKAs. In addition, concomitant use of VKAs with metformin may increase the risk of severe hypoglycemia. The clinical significance of this interaction is unknown.",
      "management_text": "Until more information is available, patients receiving VKAs with metformin should be closely monitored during concomitant therapy. The INR or prothrombin time should be checked frequently and the VKA dosage adjusted accordingly, particularly following initiation, change of dosage, or discontinuation of metformin therapy. In addition, patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18222,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23360,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Benzthiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60021,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Corticotropin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60022,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fenfluramine",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60024,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Orciprenaline",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60027,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Metolazone",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60030,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nicotinamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60031,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Phenylpropanolamine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60032,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60034,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tolazamide",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60036,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trichlormethiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60037,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Danazol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78439,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Esterified estrogens",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78974,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Estramustine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78975,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78976,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Propiomazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78980,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ritodrine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78981,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Terbutaline",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78982,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Thiethylperazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78983,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78984,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dopamine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 90549,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Niacin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98345,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Cinoxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 100394,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nalidixic acid",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 100409,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Enoxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108253,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108254,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Isoprenaline",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108255,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Norepinephrine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108256,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Polythiazide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108257,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111278,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Moderate",
      "effect": "Due to the carbohydrate content in the excipients, sucralfate oral suspension (but not the tablet) may interfere with the therapeutic effects of insulin and other antidiabetic agents.",
      "management_text": "Caution is advised when sucralfate oral suspension is prescribed to patients with diabetes. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of sucralfate treatment, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111279,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vilanterol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114714,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Coadministration with gilteritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the intestinal P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and/or organic cation transporter 1 (OCT1) transporters, such as dabigatran, digoxin, rosuvastatin, methotrexate, and metformin.",
      "management_text": "Until more information is available, caution is advised if gilteritinib is used concomitantly with drugs that are substrates of the intestinal P-gp, BCRP, and/or OCT1 transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever gilteritinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 137952,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Moderate",
      "effect": "Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.",
      "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 238627,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Simeprevir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 238629,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sofosbuvir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 238631,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Thyrotropin alfa",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 290384,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Norgestimate",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 292797,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Desogestrel",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 293035,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bictegravir",
      "severity": "Moderate",
      "effect": "Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.",
      "management_text": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 295506,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Paritaprevir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 297985,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dasabuvir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 297986,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dienogest",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 298493,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Elbasvir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 299133,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Grazoprevir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 299134,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Velpatasvir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 299503,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Glecaprevir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300084,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Voxilaprevir",
      "severity": "Moderate",
      "effect": "Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.",
      "management_text": "Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 301849,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Moderate",
      "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.",
      "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17980,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17996,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Conjugated estrogens (topical)",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18006,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Moderate",
      "effect": "Coadministration with metformin may decrease the anticoagulant effects of vitamin K antagonists (VKAs). The mechanism has not been delineated, but it may involve metformin-mediated increase in the elimination rate of VKAs. In addition, concomitant use of VKAs with metformin may increase the risk of severe hypoglycemia. The clinical significance of this interaction is unknown.",
      "management_text": "Until more information is available, patients receiving VKAs with metformin should be closely monitored during concomitant therapy. The INR or prothrombin time should be checked frequently and the VKA dosage adjusted accordingly, particularly following initiation, change of dosage, or discontinuation of metformin therapy. In addition, patients receiving this combination should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18026,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diethylstilbestrol",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18029,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Moderate",
      "effect": "The major pathway for elimination of dofetilide is through glomerular filtration and active tubular secretion using the cation transport system. Competition for this elimination pathway by other drugs may potentially result in increased levels of dofetilide and increase the risk of QT interval prolongation and ventricular arrhythmias. The clinician should be aware of the potential for an interaction when dofetilide is used in combination with another medication that is excreted via this pathway.",
      "management_text": "The manufacturer recommends that the patient be closely monitored if these drugs are coadministered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18034,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Etonogestrel",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18047,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18061,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18072,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of lactic acidosis associated with the use of metformin. The precise mechanism for this interaction has not been clearly delineated. Since NSAIDs have been shown to cause a deterioration in renal function, the likelihood of lactic acidosis occurring may be increased in patients with preexisting renal impairment.",
      "management_text": "Caution and monitoring of renal function is advised if metformin is used concomitantly with NSAIDs. Dose adjustments may be considered, particularly in patients with renal impairment. Close monitoring for the development of lactic acidosis is also recommended, particularly in patients with renal impairment. Patients should contact their physician immediately if they experience potential signs and symptoms of lactic acidosis such as malaise, myalgia, respiratory distress, increasing somnolence, and nonspecific abdominal distress (especially after stabilization of metformin therapy, when gastrointestinal symptoms are uncommon). With more marked acidosis, there may also be associated hypothermia, hypotension, and resistant bradyarrhythmias. Metformin should be withdrawn promptly if lactic acidosis is suspected. Serum electrolytes, ketones, blood glucose, blood pH, lactate levels, and blood metformin levels may be useful in establishing a diagnosis. Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18073,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin human",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18074,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18079,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Moderate",
      "effect": "Coadministration of metformin with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia. Although metformin alone generally does not cause hypoglycemia under normal circumstances of use, the added therapeutic effect when combined with other antidiabetic agents may result in hypoglycemia. The risk is further increased when caloric intake is deficient or when strenuous exercise is not compensated by caloric supplementation.",
      "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used with metformin. Blood glucose should be closely monitored, and patients should be educated on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, tachycardia) and appropriate remedial actions to take if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18083,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Morphine",
      "severity": "Moderate",
      "effect": "Morphine is a cationic drug and theoretically may decrease the excretion of metformin by competing for renal tubular transport. Although this interaction has not been specifically reported for morphine, cimetidine (also a cationic drug) has been reported to interact with metformin in this manner. Increased metformin levels may increase the risk of lactic acidosis.",
      "management_text": "If morphine and metformin must be used together, particularly slow and cautious titration of metformin dosage is recommended. The maximal dose of metformin probably also should be reduced until further information about this interaction is available. Patients should be advised to monitor their blood glucose and to promptly notify their physician if they experience possible signs of lactic acidosis such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset, or other unusual symptoms.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18129,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Moxifloxacin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18130,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nelfinavir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18134,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Octreotide",
      "severity": "Moderate",
      "effect": "Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).",
      "management_text": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer's product labeling, and the antidiabetic treatment adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18138,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pegaspargase",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18149,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pegvisomant",
      "severity": "Moderate",
      "effect": "Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.",
      "management_text": "Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18150,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Phentermine",
      "severity": "Moderate",
      "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.",
      "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18157,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18159,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Moderate",
      "effect": "Ranolazine may reduce the renal clearance of drugs that are substrates of the organic cation transporter 2 (OCT2). The mechanism is inhibition of OCT2-mediated elimination by ranolazine.",
      "management_text": "It may be advisable to monitor patients for altered efficacy and safety if ranolazine must be used with an OCT2 substrate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18175,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sermorelin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18185,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trospium",
      "severity": "Moderate",
      "effect": "Coadministration with metformin may decrease the plasma concentrations of trospium. The mechanism of interaction has not been established.",
      "management_text": "Patients should be monitored for potentially diminished efficacy of trospium chloride during coadministration with metformin.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18214,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18223,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Asparaginase Escherichia coli",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33319,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Somatotropin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60035,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78977,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Moderate",
      "effect": "Limited data suggest that ACE inhibitors may potentiate the hypoglycemic effects of oral antidiabetic drugs, including metformin. The mechanism is unknown. Symptomatic and sometimes severe hypoglycemia has occurred.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if ACE inhibitors are coadministered with metformin, particularly in patients with advanced age and/or renal impairment. Dosage adjustments may be required if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs. Patients should be observed for loss of glycemic control when ACE inhibitors are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 100413,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Moderate",
      "effect": "Diuretic-induced renal impairment and dehydration may increase the risk of lactic acidosis in patients who are concomitantly taking metformin. In addition, thiazides and other diuretics may interfere with glucose control by causing hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring is recommended if diuretics are coadministered with antidiabetic agents. Patients should be advised to monitor their blood glucose and to promptly notify their doctor if they experience possible signs of lactic acidosis (such as malaise, myalgia, respiratory distress, hyperventilation, slow or irregular heartbeat, somnolence, abdominal upset) or loss of glycemic control. Dose adjustments of metformin may be required. Likewise, patients should be observed for hypoglycemia if diuretics are withdrawn from their therapeutic regimen.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108259,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Adefovir dipivoxil",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of adefovir and/or the coadministered drug(s).  The mechanism is competitive inhibition of renal excretion.  Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, valacyclovir, tenofovir, ganciclovir, and valganciclovir.",
      "management_text": "Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 238607,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Moderate",
      "effect": "Coadministration with fedratinib may decrease the renal clearance of drugs that are excreted via organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2-K.",
      "management_text": "Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 238612,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Clobetasol (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18002,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Clocortolone (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18003,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Desonide (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18016,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Desoximetasone (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18017,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fluocinonide (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18050,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fluticasone (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18053,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Garlic",
      "severity": "Minor",
      "effect": "Some authors suggest that garlic may potentiate the hypoglycemic effect of insulin and oral antidiabetic agents, although supportive evidence is scarce.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18057,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Minor",
      "effect": "Itraconazole, a potent inhibitor of CYP450 3A4, does not appear to significantly affect the pharmacokinetics of available oral hypoglycemic agents, most of which are primarily metabolized by CYP450 2C8 (pioglitazone, rosiglitazone, repaglinide) or 2C9 (nateglinide, sulfonylureas). In most patients, no change in antidiabetic effect was reported. No specific precautions should be necessary during coadministration of most oral hypoglycemic agents with itraconazole. However, dosage adjustments may be necessary if an interaction is suspected.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18098,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ulobetasol (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 60025,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Prednicarbate (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 60033,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Halcinonide (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 78978,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Flurandrenolide (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 98344,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Minor",
      "effect": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the renal transporter multidrug and toxin extrusion protein 1 (MATE1).",
      "management_text": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the renal transporter multidrug and toxin extrusion protein 1 (MATE1).  In vitro studies indicate that selpercatinib inhibits MATE1 at clinically relevant concentrations.  However, the clinical significance of this finding has not been established.  No clinically significant differences in glucose levels were observed when metformin, a MATE1 substrate, was coadministered with selpercatinib.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 238628,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Alclometasone (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 12404,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Amcinonide",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 17969,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Diflorasone (topical)",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18030,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Midodrine",
      "severity": "Minor",
      "effect": "Theoretically, the coadministration with midodrine may result in decreased clearance of drugs that are primarily eliminated by active tubular secretion such as metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, and triamterene. The proposed mechanism is competitive inhibition of renal excretion by desglymidodrine, the active metabolite of midodrine. Patients receiving midodrine in combination with drugs that undergo active tubular secretion should be monitored for excessive effects of one or both drugs.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 18126,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fluocinolone acetonide",
      "severity": "Minor",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.",
      "management_text": "Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 238614,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methadone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201598,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pimecrolimus",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201599,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201600,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Minoxidil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201601,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201602,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Mirtazapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201603,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Timolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201604,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trihexyphenidyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201605,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Palonosetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201606,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sorafenib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201607,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201608,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nisoldipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201609,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Mupirocin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201610,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201611,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pramipexole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201612,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methylphenidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201613,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methocarbamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201614,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201615,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201616,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Prazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201617,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Verteporfin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201618,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Montelukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201619,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201620,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Raloxifene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201622,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201623,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Entacapone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201624,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Zidovudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201625,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201626,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxycodone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201627,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201628,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxaliplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201629,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201630,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201631,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Gadoversetamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201632,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nortriptyline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201633,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201634,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pyridostigmine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201635,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Zafirlukast",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201636,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201637,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methotrexate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201638,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201639,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201640,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nizatidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201642,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201643,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxandrolone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201644,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Testosterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201645,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201646,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nystatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201647,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Stavudine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201648,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201649,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sumatriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201650,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tamoxifen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201652,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tobramycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201653,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201654,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nitrofurantoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201655,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Eplerenone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201656,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201657,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201658,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Paroxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201659,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Nitroglycerin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201660,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Riluzole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201661,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Modafinil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201662,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tretinoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201663,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tetracycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201664,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Potassium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201665,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Olopatadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201667,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tirofiban",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201668,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxcarbazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201669,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Primidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201670,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201671,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pentoxifylline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201672,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ribavirin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201673,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Propofol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201674,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tadalafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201675,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201676,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Dacarbazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201677,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Temozolomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201678,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Terbinafine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201679,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Vardenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201680,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Risedronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201681,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201682,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ondansetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201683,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Bimatoprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201684,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tiagabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201685,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Metronidazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201686,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Almotriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201687,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Misoprostol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201688,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Fulvestrant",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201689,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Rizatriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201690,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201691,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pindolol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201692,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Zaleplon",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201693,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201694,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Desloratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201695,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Methyldopa",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201696,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Selenium Sulfide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201697,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201698,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201699,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Rivastigmine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201700,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Exemestane",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201701,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Neomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201702,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Minocycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201703,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201704,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201706,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Selegiline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201707,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201708,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Oxybutynin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201709,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Tegaserod",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201710,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Pilocarpine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201711,
      "ingredient1": "Metformin hydrochloride"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201712,
      "ingredient1": "Metformin hydrochloride"
    }
  ]
}